Resultados de procura - Ignacio Garrido‐Laguna

Limitar resultados
  1. 1
    TIGIT: a novel immunotherapy target moving from bench to bedside

    TIGIT: a novel immunotherapy target moving from bench to bedside por Benjamin L. Solomon, Ignacio Garrido‐Laguna

    Publicado 2018
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Novel Therapeutic Targets in Non-small Cell Lung Cancer

    Novel Therapeutic Targets in Non-small Cell Lung Cancer por Filip Janků, Ignacio Garrido‐Laguna, Luboš Petruželka, David J. Stewart, Razelle Kurzrock

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle

    Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle por Snehal Gajiwala, Anna Torgeson, Ignacio Garrido‐Laguna, Conan G. Kinsey, Shane Lloyd

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  4. 4
    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes

    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes por Filip Janků, Hesham M. Amin, Dan Yang, Ignacio Garrido‐Laguna, Jonathan C. Trent, Razelle Kurzrock

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer

    Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer por Anna Torgeson, Shane Lloyd, Dustin Boothe, Randa Tao, Jonathan Whisenant, Ignacio Garrido‐Laguna, George M. Cannon

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer

    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer por Michael J. Pishvaian, Ignacio Garrido‐Laguna, Stephen V. Liu, Pratik S. Multani, Edna Chow‐Maneval, Christian Rolfo

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma

    <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma por Carter Norton, Matthew Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P. Soares, Christopher Nevala-Plagemann, Ignacio Garrido‐Laguna, Vaia Florou

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center por Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers por Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors por Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

    A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer por Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Elizabeth De Oliveira, Belén Rubio‐Viqueira, Steven J. Strawn, Michael J. Wick, James Martell, David Sidransky

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

    A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors por Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, Ignacio Garrido‐Laguna, John H. Strickler, Kathleen N. Moore, Robert Stagg, Ann M. Kapoun, Leonardo Faoro, Sunil Sharma

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors por Filip Janků, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations

    PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations por Filip Janků, Jennifer J. Wheler, Shannon N. Westin, Stacy Moulder, Aung Naing, Apostolia M. Tsimberidou, Siqing Fu, Gerald S. Falchook, David S. Hong, Ignacio Garrido‐Laguna, Rajyalakshmi Luthra, J. Jack Lee, Karen H. Lu, Razelle Kurzrock

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer por Maria Cristina Villarroel, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Ana De Jesus‐Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison P. Klein, Daniel A. Laheru, Ross C. Donehower, Manuel Hidalgo

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

    PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes por Filip Janků, Jennifer J. Wheler, Aung Naing, Vanda M. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido‐Laguna, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Stacy Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong, Razelle Kurzrock

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors

    First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors por Ignacio Garrido‐Laguna, Ian E. Krop, Howard A. Burris, Erika Hamilton, Fadi Braiteh, Amy Weise, Maysa Abu‐Khalaf, Theresa L. Werner, Steven Pirie‐Shepherd, Christopher J. Zopf, Mani Lakshminarayanan, Jaymes Holland, Raffaele Baffa, David S. Hong

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

    Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors por Anthony B. El-Khoueiry, James S. Clarke, Tobias Neff, T. Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido‐Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J. O’Dwyer, Adam Cuker, Albiruni R. Abdul Razak

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC

    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC por Vaia Florou, Andrew Elliott, Matthew H. Bailey, David Stone, Kajsa E. Affolter, Heloisa P. Soares, Christopher Nevala-Plagemann, Courtney L. Scaife, Phillip Walker, W. Michael Korn, Emil Lou, Rachna T. Shroff, Peter J. Hosein, Ignacio Garrido‐Laguna

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

    652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (... por Kathryn C. Arbour, Salman Rafi Punekar, Ignacio Garrido‐Laguna, David S. Hong, Brian M. Wolpin, Meredith S. Pelster, M. Barve, Alexander Starodub, D. Sommerhalder, Sam S. Chang, Y. Zhang, Zeena Salman, X. Wang, Corinne E. Gustafson, Alexander I. Spira

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: